About: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
Creator	Fafi-Kremer, Samira Schneider, Francis Castelain, Vincent Clere-Jehl, Raphaël Fagot Gandet, Florence Helms, Julie Leonard-Lorant, Ian Merdji, Hamid Mertes, Paul-Michel Meziani, Ferhat Ohana, Mickaël Sattler, Laurent Tacquard, Charles Delabranche, Xavier Severac, François Anglés-Cano, Eduardo Grunebaum, Lélia Schenck, Malika
Source	Medline; PMC; WHO
abstract	PURPOSE: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. METHODS: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients. RESULTS: 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups. CONCLUSION: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-020-06062-x) contains supplementary material, which is available to authorized users.
has issue date	2020-05-04(xsd:dateTime)
bibo:doi	10.1007/s00134-020-06062-x
bibo:pmid	32367170
has license	no-cc
sha1sum (hex)	c7bc3c3c54a821a5b531db1e1dcbcabd4ff7ff1b
schema:url	https://doi.org/10.1007/s00134-020-06062-x
resource representing a document's title	High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
has PubMed Central identifier	PMC7197634
has PubMed identifier	32367170
schema:publication	Intensive Care Med
resource representing a document's body	covid:c7bc3c3c54a821a5b531db1e1dcbcabd4ff7ff1b#body_text
is schema:about of	named entity 'infection' named entity 'thrombosis' named entity 'multicenter' named entity 'THROMBOTIC' named entity 'COVID-19' named entity 'thrombotic' named entity 'assess' named entity 'infection' named entity 'thrombotic' named entity 'prospective cohort study' named entity 'medical history' named entity 'ARDS' named entity 'antigen' named entity 'D-dimer' named entity 'hematoma' named entity 'ISTH' named entity 'R software' named entity 'COVID' named entity 'thromboplastin' named entity 'Propensity scores' named entity 'lower limb ischemia' named entity 'CTPA' named entity 'coagulopathy' named entity 'fibrinogen' named entity 'dehydration' named entity 'D-dimer' named entity 'COVID-19' named entity 'continuous infusion' named entity 'pelvis' named entity 'coagulation disorders' named entity 'COVID' named entity 'lung inflammation' named entity 'viruses' named entity 'antibody' named entity 'coronavirus disease 2019' named entity 'Overhydration' named entity 'iodine' named entity 'SAPS II' named entity 'renal injury' named entity 'dimers' named entity 'abdomen' named entity 'DIC' named entity 'septic shock' named entity 'ICU' named entity 'prospective cohort' named entity 'aPTT' named entity 'inflammation' named entity 'fibrin' named entity 'coagulation' named entity 'pulmonary embolism' named entity 'capillaries' named entity 'evolution' named entity 'phenotype' named entity 'Berlin' named entity 'pulmonary embolisms' named entity 'ischemic strokes' named entity 'tertiary hospital' named entity 'PAI-1' named entity 'fibrin' named entity 'HIF1α' named entity 'plasma membrane' named entity 'COVID-19' named entity 'aPTT' named entity 'antiviral treatment'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software